- Main
The dopamine receptor antagonist trifluoperazine prevents phenotype conversion and improves survival in mouse models of glioblastoma
- Bhat, Kruttika;
- Saki, Mohammad;
- Vlashi, Erina;
- Cheng, Fei;
- Duhachek-Muggy, Sara;
- Alli, Claudia;
- Yu, Garrett;
- Medina, Paul;
- He, Ling;
- Damoiseaux, Robert;
- Pellegrini, Matteo;
- Zemke, Nathan R;
- Nghiemphu, Phioanh Leia;
- Cloughesy, Timothy F;
- Liau, Linda M;
- Kornblum, Harley I;
- Pajonk, Frank
Published Web Location
https://doi.org/10.1073/pnas.1920154117Abstract
Glioblastoma (GBM) is the deadliest adult brain cancer, and all patients ultimately succumb to the disease. Radiation therapy (RT) provides survival benefit of 6 mo over surgery alone, but these results have not improved in decades. We report that radiation induces a glioma-initiating cell phenotype, and we have identified trifluoperazine (TFP) as a compound that interferes with this phenotype conversion. TFP causes loss of radiation-induced Nanog mRNA expression, and activation of GSK3 with consecutive posttranslational reduction in p-Akt, Sox2, and β-catenin protein levels. TFP did not alter the intrinsic radiation sensitivity of glioma-initiating cells (GICs). Continuous treatment with TFP and a single dose of radiation reduced the number of GICs in vivo and prolonged survival in syngeneic and patient-derived orthotopic xenograft (PDOX) mouse models of GBM. Our findings suggest that the combination of a dopamine receptor antagonist with radiation enhances the efficacy of RT in GBM by preventing radiation-induced phenotype conversion of radiosensitive non-GICs into treatment-resistant, induced GICs (iGICs).
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.